CompletedNCT05668897Updated Oct 12, 2023

Safety, Tolerability and Pharmacokinetic Characteristics Evaluation on GST-HG171 Tablets

A Phase 1 interventional study of GST-HG171 and placebo of GST-HG171 in COVID-19, sponsored by Fujian Akeylink Biotechnology Co., Ltd.. Completed at 1 site in China. Open to participants aged 18 Years to 50 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2023-10-12.

Sponsored by Fujian Akeylink Biotechnology Co., Ltd. · Phase 1, Interventional, and Treatment

Phase: Phase 1
Study type: Interventional
Enrollment: 78
Allocation: Randomized
Ages: 18 Years to 50 Years
Sex: All

Study summary

To Evaluate the Safety, Tolerability and Pharmacokinetics on GST-HG171 Tablets in Randomized, Double-blind, Placebo-controlled Single-dose and Multiple-dose ascending Phase Ia Clinical Trials in Healthy Subjects

Conditions studied

COVID-19

In context

Lead sponsor

Fujian Akeylink Biotechnology Co., Ltd. is the lead sponsor of 12 studies on the registry; 5 are open to participants now.

Counted across the registry records on this site, refreshed daily.

Who can participate

Ages eligible: 18 Years to 50 Years
Sexes eligible: All
Accepts healthy volunteers: Yes

Inclusion criteria

Sign the informed consent before the trial and fully understand the content, process and possible adverse reactions of the trial;
Ability to complete research in accordance with test plan requirements;
Subjects (including partners) are willing to take effective pregnancy avoidance measures within 6 months after screening to the last study drug administration;
Male and female healthy subjects aged 18 to 50 years (including 18 and 50 years old);
Male subjects weigh no less than 50 kg, and female subjects weigh no less than 45 kg. Body mass index (BMI) = body weight (kg) / height 2 (m2), body mass index is in the range of 18 \~ 28 kg / m2 (including critical value);
Physical examination, normal or abnormal vital signs have no clinical significance.

Exclusion criteria

Exclusion Criteria:

Allergies (multiple drugs and food allergies);
Those who smoked more than 5 cigarettes per day in the 3 months before the trial;
Have a history of drug abuse and / or alcoholism (drink 14 units of alcohol per week: 1 unit = 285 mL of beer, or 25 mL of spirits, or 100 mL of wine);
Blood donation or massive blood loss (> 400 mL) within three months before screening;
Have a history of dysphagia or any gastrointestinal disease that affects drug absorption, including a history of frequent nausea or vomiting caused by any cause;
Have any disease that increases the risk of bleeding, such as hemorrhoids, acute gastritis, or gastric and duodenal ulcers;
Have taken the study drug or participated in the drug clinical trial within three months before taking the study drug;
Have Intended to take any drug that changes the activity of drug metabolizing enzyme 28 days before screening or during the study, including strong inhibitors and inducers that affect the metabolizing enzyme;
Took any prescription drugs or herbs within 14 days before screening, or took over-the-counter drugs or any vitamin products within 7 days before screening;
Vaccinated within 14 days before screening or planned to be vaccinated during the study;
Those who have taken special diets (including dragon fruit, mango, grapefruit, etc.) or have vigorous exercise or other factors affecting drug absorption, distribution, metabolism, excretion, etc. within 2 weeks before screening;
Those who cannot tolerate high fat (about 50% of the total calories) and high calorie (about 800\~1000 calories) standard meals (only applies to subjects participating in the food effect study);
Abnormal ECG has clinical significance;
Female subjects were breastfeeding or had a positive serum pregnancy result during the screening period or during the study;
Clinical laboratory examinations are abnormal and clinically significant, or find the following diseases with clinical significance (including but not limited to gastrointestinal tract, kidney, liver, nerve, blood, endocrine, tumor, lung, Immune, mental or cardiovascular disease) within 6 months before screening;
Positive screening for viral hepatitis (including hepatitis B and C), AIDS antigen / antibody, and Treponema pallidum antibody;
Acute disease or concomitant medication occurs from the screening stage to before study medication;
Ingested chocolate, any caffeinated or xanthine-rich food or drink 24 hours before taking the study drug;
People who have a positive urine drug screen or have a history of drug abuse or have used drugs within the past five years;
The investigator believes that there are other subjects who are not suitable for participating in this trial.

Study design

Phase: Phase 1
Primary purpose: Treatment
Allocation: Randomized
Intervention model: Parallel assignment
Masking: Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment: 78 participants (actual)

Study arms

Experimental
Single-dose ascending group
SAD study cotains at least 4 cohorts at dosage of 150mg, 300mg, 600mg and 900mg. Each cohort enrolls 6 subjects receive study drug.
Drug: GST-HG171
Placebo comparator
SAD placebo comparator group
SAD study cotains at least 4 cohorts at dosage of 150mg, 300mg, 600mg and 900mg. Each cohort enrolls 2 subjects receive placebo.
Drug: placebo of GST-HG171
Experimental
Multi-dose ascending group
MAD study cotains 1-3 cohorts which were evaluated in SAD study to be tolerated . Each cohort enrolls 6 subjects receive study drug.
Drug: GST-HG171
Placebo comparator
MAD placebo comparator group
MAD study cotains 1-3 cohorts which were evaluated in SAD study to be tolerated . Each cohort enrolls 2 subjects receive placebo.
Drug: placebo of GST-HG171
Experimental
Food effect study
FE study cotains at least 1 cohort which were evaluated in SAD study to be tolerated . Each cohort enrolls 12 subjects receive study drug on fast or fed condition.
Drug: GST-HG171

Interventions

DrugGST-HG171
This study includes single-dose ascending and multiple-dose ascending studies. SAD study contains at least 4 dose groups of 150 mg, 300 mg, 600 mg and 900 mg. MAD study contains 1-3 dose groups which were evaluated in SAD study to be tolerated.
Drugplacebo of GST-HG171
This study includes single-dose ascending and multiple-dose ascending studies. SAD study contains at least 4 dose groups of 150 mg, 300 mg, 600 mg and 900 mg. MAD study contains 1-3 dose groups which were evaluated in SAD study to be tolerated.

What researchers measure

Primary outcomes

safety and tolerability
Number of Participants With Treatment-Related Adverse Events as Assessed by CTCAE v5.0
Time frame: SAD up to Day 5 and MAD up to Day 9

Secondary outcomes

Peak Plasma Concentration (Cmax)
Plasma samples were collected at different points for pharmacokinetic analysis
Time frame: Measured on -0.5, 0.25, 0.5, 0.75, 1, 1.25, 1.5, 2, 3, 4, 6, 8, 12, 24, 48, 72, 96hours in single-dosing. In the multiple dose group, measured on -0.5, 0.25, 0.5, 0.75, 1, 1.25, 1.5, 2, 3, 4, 6, 8, 12hours on Day1, more details in protocol.
Area Under Curve (AUC)
Plasma samples were collected at different points for pharmacokinetic analysis
Time frame: Measured on -0.5, 0.25, 0.5, 0.75, 1, 1.25, 1.5, 2, 3, 4, 6, 8, 12, 24, 48, 72, 96hours in single-dosing. In the multiple dose group, measured on -0.5, 0.25, 0.5, 0.75, 1, 1.25, 1.5, 2, 3, 4, 6, 8, 12hours on Day1, more details in protocol.
T1/2
Plasma samples were collected at different points for pharmacokinetic analysis
Time frame: Measured on -0.5, 0.25, 0.5, 0.75, 1, 1.25, 1.5, 2, 3, 4, 6, 8, 12, 24, 48, 72, 96hours in single-dosing. In the multiple dose group, measured on -0.5, 0.25, 0.5, 0.75, 1, 1.25, 1.5, 2, 3, 4, 6, 8, 12hours on Day1, more details in protocol.
Cl/F
Plasma samples were collected at different points for pharmacokinetic analysis
Time frame: Measured on -0.5, 0.25, 0.5, 0.75, 1, 1.25, 1.5, 2, 3, 4, 6, 8, 12, 24, 48, 72, 96hours in single-dosing. In the multiple dose group, measured on -0.5, 0.25, 0.5, 0.75, 1, 1.25, 1.5, 2, 3, 4, 6, 8, 12hours on Day1, more details in protocol.
Ae(0~120h)
Plasma samples were collected at different points for pharmacokinetic analysis
Time frame: Measured on -0.5, 0.25, 0.5, 0.75, 1, 1.25, 1.5, 2, 3, 4, 6, 8, 12, 24, 48, 72, 96hours in single-dosing. In the multiple dose group, measured on -0.5, 0.25, 0.5, 0.75, 1, 1.25, 1.5, 2, 3, 4, 6, 8, 12hours on Day1, more details in protocol.
Fe(0~120h)
Plasma samples were collected at different points for pharmacokinetic analysis
Time frame: Measured on -0.5, 0.25, 0.5, 0.75, 1, 1.25, 1.5, 2, 3, 4, 6, 8, 12, 24, 48, 72, 96hours in single-dosing. In the multiple dose group, measured on -0.5, 0.25, 0.5, 0.75, 1, 1.25, 1.5, 2, 3, 4, 6, 8, 12hours on Day1, more details in protocol.

Study locations

1 site

The first hospital of Jilin University
Changchun, Jilin 130021, China

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

Updates

Tracking since Sep 25, 2026

No changes since tracking began. The registry record was last updated on Oct 12, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗

Registry details

Key details

Study ID: NCT05668897
Lead sponsor: Fujian Akeylink Biotechnology Co., Ltd.
Responsible party: Sponsor
First posted: Dec 30, 2022
Start date: Oct 1, 2022
Primary completion: Dec 2, 2022
Completion: Dec 8, 2022
Last update: Oct 12, 2023

Oversight

FDA-regulated drug: No
FDA-regulated device: No

View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Dec 2022. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Other studies from this sponsor

Fujian Akeylink Biotechnology Co., Ltd.

Start the discussion